deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04569084

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Tanabe Pharma America, Inc.

Conditions ALS
Interventions MT-1186 Placebo
Updated 30 times since 2020 Last updated: Dec 12, 2025 Started: Nov 13, 2020 Primary completion: Sep 29, 2023 Completion: Sep 29, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Futility was met.

Other terminated trials from Tanabe Pharma America, Inc.

More terminations from Tanabe Pharma America, Inc.

This PHASE3 trial investigates ALS and is currently terminated or withdrawn. Tanabe Pharma America, Inc. leads this study, which shows 30 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Oct 2023 · 4 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

30 versions recorded
  1. Jan 2026 — Present [monthly]

    Terminated PHASE3

  2. Oct 2025 — Jan 2026 [monthly]

    Terminated PHASE3

  3. Sep 2025 — Oct 2025 [monthly]

    Terminated PHASE3

  4. Apr 2025 — Sep 2025 [monthly]

    Terminated PHASE3

  5. Sep 2024 — Apr 2025 [monthly]

    Terminated PHASE3

Show 25 earlier versions
  1. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  2. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

  3. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  5. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  8. Jan 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  9. Jun 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  10. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  11. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  12. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  13. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  14. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  15. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  16. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  17. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  18. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  19. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  20. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  21. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  22. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  23. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  24. Nov 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  25. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tanabe Pharma America, Inc.
Data source: Tanabe Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .